VERAXA BIOTECH
VERAXA Biotech specializes in ADC development combining cutting-edge solutions for targeted antibody discovery and bioconjugation.
VERAXA BIOTECH
Industry:
Biotechnology
Address:
Heidelberg, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.veraxa.com
Total Employee:
11+
Status:
Active
Technology used in webpage:
Amazon
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Arcadia Science
Arcadia Science is a Research and development company leveraging the biology of emerging research organisms.
CDR-Life AG
CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.
DigitalHealth.London Accelerator
The Accelerator aims to speed up development of digital innovations across health and care, and pioneer their adoption by the NHS.
NEUWAY Pharma
NEUWAY is focusing on the preclinical and clinical development of innovative therapeutics for treatment of orphan brain diseases
RJH Biosciences
RJH Biosciences focus on development of transfection reagents and delivery agents for nucleic acids.
TargImmune Therapeutics
TargImmune Therapeutics is focused on drug development using novel targeted onco-immunotherapies.
Velabs Therapeutics
Velabs Therapeutics is a pioneer in microfluidics-based technologies for functional screening of antibodies.
Vetigenics
Vetigenics discovers and develops antibody-based immunotherapies to treat cancer and chronic diseases in companion animals
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-12-29 | Synimmune GmbH | Synimmune GmbH acquired by VERAXA Biotech | N/A |
Official Site Inspections
http://www.veraxa.com Semrush global rank: 13.71 M Semrush visits lastest month: 75
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 99.83.190.102
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "VERAXA Biotech"
Veraxa
At VERAXA Biotech, we are building a premier engine for the discovery and development of next-generation antibody-based therapeutics. Contact us. About us. Careers Partnering. Pipeline. …See details»
Our approach - Veraxa
At VERAXA, we are building an R&D organization suited to meet this future demand. A strong history in ADC development. VERAXA has established a strong position in ADC development. …See details»
VERAXA Biotech - Crunchbase Company Profile
Organization. VERAXA Biotech . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. VERAXA …See details»
Veraxa Biotech - Org Chart, Teams, Culture & Jobs - The Org
View Veraxa Biotech's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
VERAXA Biotech and Voyager Acquisition Corp. Announce …
5 days ago VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") …See details»
VERAXA Biotech GmbH - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... VERAXA is an early-stage …See details»
Veraxa 2025 Company Profile: Valuation, Funding & Investors
When was Veraxa founded? Veraxa was founded in 2017. Where is Veraxa headquartered? Veraxa is headquartered in Heidelberg, Germany. What is the size of Veraxa? Veraxa has 39 …See details»
VERAXA Biotech - Funding, Financials, Valuation & Investors
Dec 29, 2023 VERAXA Biotech has acquired Synimmune GmbH on Dec 29, 2023. Acquisitions. Edit Acquisitions Section. Number of Acquisitions 1. VERAXA Biotech has acquired …See details»
VERAXA Biotech GmbH - Drug pipelines, Patents, Clinical trials
With this clinical asset, VERAXA strengthens its internal cancer pipeline of innovative antibodies and antibody-drug conjugates (ADCs). AML, characterized by its prevalence in individuals …See details»
Superior cancer therapeutics using transformative innovations
Building a unique pipeline. With a strong foundation in ADCs and our lead program in clinical studies in AMLSee details»
Veraxa Biotech AG – Swiss Biotech
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotech industry. To support its members, the association works to secure favorable framework …See details»
VERAXA and Voyager to Create Combined Business for Advancing …
5 days ago “VERAXA is committed to developing and delivering the next wave of safe and highly efficacious cancer therapies. Our platform technologies can be applied to empower multiple …See details»
Swiss biotech firm Veraxa to list on Nasdaq in $1.64 billion SPAC …
5 days ago Swiss biotech investor Xlife Sciences AG said on Wednesday its portfolio company Veraxa Biotech AG would list on U.S. exchange Nasdaq in a $1.64 billion merger deal with a …See details»
Veraxa to go public in $1.6bn SPAC deal with Voyager
4 days ago Veraxa said that it will be pursuing multiple strategic partnerships and licensing opportunities in 2025 and 2026. Veraxa’s CEO Christoph Antz said the company’s platform is …See details»
VERAXA Biotech | The Pharmaletter
4 days ago In April 2025, VERAXA announced a definitive business combination agreement with Voyager Acquisition Corp., a special purpose acquisition company (SPAC), to become a …See details»
VERAXA Biotech AG and Voyager Acquisition Corp.
5 days ago Summary. On April 23, 2025, VERAXA Biotech AG and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the …See details»
Voyager Acquisition Corp. and VERAXA Biotech Announce …
5 days ago The combination will result in VERAXA becoming a publicly traded company on Nasdaq under the ticker symbol “VERX”, with a pre-money equity valuation of $1.3 billion and …See details»
Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal
5 days ago Zurich-based start-up Veraxa Biotech has reached a deal to merge with special purpose acquisition company (SPAC) Voyager, gaining a listing on the Nasdaq that will give it …See details»
Veraxa Biotech Set to Go Public with $1.6 Billion SPAC Merger: A …
4 days ago Veraxa aims to leverage artificial intelligence to reduce side effects and maximize market impact in cancer treatment. Overview of the SPAC Merger and Financial Implications. …See details»
Veraxa
5 days ago ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 --VERAXA Biotech AG(“VERAXA” or the “Company”), an emerging leader in designing novel …See details»